International Maritime Exchange ASA (Imarex) to be listed on Oslo Børs
The Board of Oslo Børs resolved to admit shares in Imarex ASA to listing on Oslo Børs. Admission to listing is conditional on the company’s forthcoming share issue creating a sufficiently wide distribution of its shares in terms of the number of shareholders holding at least one round lot to satisfy the requirements.
The Board authorised the President of Oslo Børs to decide whether the company should be listed on the SMB List or the Main List and to fix the date of the first day of listing, which is to be no later than 27 April 2005.
About Imarex
Imarex (The International Maritime Exchange) is the world's only authorized and regulated marketplace for trading and clearing of freight derivatives – the fastest growing shipping market in the world. Members of the Exchange include more than 80 of the world’s largest ship owners, oil companies, banks and commodity houses. Membership is growing rapidly, and members are trading financial futures contracts linked to the cost of ocean freight electronically on screen and in ever increasing volumes. Imarex was founded in 2001, and has 22 employees in Oslo and Singapore. Imarex owns 16.7% of NOS (The Norwegian Futures and Options Clearing House).
Polimoon ASA to be listed on Oslo Børs
The Board of Oslo Børs resolved to admit shares in Polimoon ASA to listing on Oslo Børs. The Board agreed to exempt the company from the requirement that a listed company must have been in existence for at least three years. Admission to listing is conditional on the company’s forthcoming share issue creating a sufficiently wide distribution of its shares in terms of the number of shareholders holding at least one round lot and free float in the shares. It is also a condition for admission to listing that the composition of the company’s board of directors satisfies the requirements of Oslo Børs prior to ordinary listing.
Admission to listing is conditional on the company producing a prospectus that satisfies the requirements of the Stock Exchange Regulations for a new listing.
The Board authorised the President of Oslo Børs to decide whether the company should be listed on the SMB List or the Main List and to fix the date of the first day of listing, which is to be no later than 29 April 2005.
About Polimoon
Polimoon Group holds a leading position within manufacturing, developing and selling of plastic products with 20 operations in eleven European countries. Polimoon develops, manufactures and sells a wide range of packaging products within the consumer, chemical and medical industries as well as components to the automotive industry. In addition the Group has some production of customised products to other industries, such as the marine and leisure industry. Polimoon has approximately 2000 employees with 450 employed in Norway, where also head office is located. In 2004 Polimoon Group had a turnover of 2494 million kroner and an EBITA of 274 million kroner.
APL ASA to be listed on Oslo Børs
The Board of Oslo Børs resolved to admit shares in APL ASA to listing on the SMB-list on Oslo Børs. The Board agreed to exempt the company from the requirement that a listed company must have carried on the major part of its activities for at least three years. Admission to listing is conditional on the company achieving a sufficiently wide distribution of its shares in terms of the number of shareholders holding at least one round lot and free float in the shares. It is also a condition for admission to listing that the composition of the company’s board of directors satisfies the requirements of Oslo Børs prior to listing.
First day of listing for APL will be Friday 18 March.
About APL
APL, headquartered in Arendal, Norway, is a supplier of Production Systems and Loading Systems to the offshore oil and gas industry and has focus on patented products and services in the interface between the seabed and the vessel. Production Systems include products and services related to permanent mooring and production of oil and gas by FPSOs and FSOs. Loading Systems include products and services related to the loading of oil and gas from Production Platforms, SPARs, FPSOs or FSOs into or from a shuttle tanker or offshore terminal. APL realized a strong order intake in 2004 and the order book is currently at a historically high level.
Violation charge for PA Resources AB
The Board of Oslo Børs resolved to impose a violation charge on PA Resources AB of three times the company’s annual listing fee, i.e. NOK 330,000, for a breach of the duty to provide information pursuant to Section 5-2, first paragraph, and Section 5-3 of the Stock Exchange Regulations.
On Wednesday 17 November 2004, PA Resources AB signed an agreement with the English company Soco International plc to buy 100% of the share capital of Soco Overseas, giving it an ownership interest in the Zarat licence in the Gulf of Gabes off the Tunisian coast. The company published a stock exchange announcement about the agreement through the Oslo Børs information system on Friday 19 November 2004.
In case of an agreement to acquire a business where the operating revenues, result for the year or market value of the business acquired constitutes 15% or more of the corresponding figure for the issuer prior to the acquisition, the issuer must publish information on the acquisition including pro forma figures as a stock exchange announcement. The acquisition of Soco Overseas represented more than the total operating revenue of PA Resources AB for 2003. Pro forma accounting figures in respect of the acquisition were first published in a prospectus dated the 14 February 2005.
This decision may be appealed to the Oslo Børs Appeals Committee. Any appeal must be submitted within two weeks.
Violation charge for PhotoCure ASA
The Board of Oslo Børs resolved to impose a violation charge on PhotoCure ASA equivalent to the company’s annual listing fee, i.e. NOK 110,000, for a breach of the duty to provide information pursuant to Section 5-2, first paragraph, of the Stock Exchange Regulations.
PhotoCure AB received a telefax during the night of Thursday 2 December 2004 from the US Food and Drug Administration (FDA) informing it that the current data it had submitted was insufficient for approval of Metvix for the treatment of skin cancer in the USA. PhotoCure ASA first published information on the FDA decision through the Oslo Børs information system at 11.23 on the morning of Friday 3 December.
This decision may be appealed to the Oslo Børs Appeals Committee. Any appeal must be submitted within two weeks.
